| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
| 1-Month | 1,750.000 +3.14% on 04/25/24 | | 1,938.000 -6.86% on 03/28/24 | -78.000 (-4.14%) since 03/25/24 |
| 3-Month | 1,750.000 +3.14% on 04/25/24 | | 2,165.000 -16.63% on 02/22/24 | -60.500 (-3.24%) since 01/25/24 |
| 52-Week | 1,711.000 +5.49% on 11/30/23 | | 2,222.000 -18.77% on 08/10/23 | -15.500 (-0.85%) since 04/25/23 |
Bio-Thera Solutions, Ltd. (688177.SH) and Hikma Pharmaceuticals PLC (LSE: HIK) today announced that they have entered into a commercialization and license agreement to commercialize BAT2206, a monoclonal...
Melinta Therapeutics (Melinta) and Hikma Pharmaceuticals PLC (Hikma) today announced they have entered into an exclusive licensing agreement for Vabomere ® (meropenem and vaborbactam) and Orbactiv ®...
Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, and Hikma Pharmaceuticals, a multi-national pharmaceutical...
LONDON, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today's...
| 3rd Resistance Point | 1,866.667 |
| 2nd Resistance Point | 1,852.333 |
| 1st Resistance Point | 1,832.667 |
| Last Price | 1,809.000 |
| 1st Support Level | 1,798.667 |
| 2nd Support Level | 1,784.333 |
| 3rd Support Level | 1,764.667 |
| 52-Week High | 2,222.000 |
| Fibonacci 61.8% | 2,026.798 |
| Fibonacci 50% | 1,966.500 |
| Fibonacci 38.2% | 1,906.202 |
| Last Price | 1,809.000 |
| 52-Week Low | 1,711.000 |